PACAP-38 Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.

Bioavailability Complete (about 100%) — delivered straight into the bloodstream.

Standard Dose

10 pmol/kg/min

Frequency

Continuous infusion

Duration

20-minute single infusion

Standardized human experimental-medicine provocation dose; 10 pmol/kg/min over 20 min was selected as the optimal/maximum tolerated rate after dose-finding (5-20 pmol/kg/min) and is reproduced across headache-model trials [6][7][8]. Used as a research provocation agent, not an approved therapeutic.

Timing

Best time to take

PACAP-38 is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.

With food?

IV administration of PACAP-38 is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.

If stacking

PACAP-38 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

+You've tolerated the current dose for the recommended period without significant side effects

+Therapeutic goals haven't been met at the current dose level

+Your healthcare provider recommends dose escalation based on your response

+Lab work or clinical assessments support a higher dose

Decrease if

-Side effects are bothersome or impacting daily life despite management strategies

-You experience any signs of an adverse reaction

-Lab results indicate the need for dose reduction

-Your healthcare provider recommends a lower dose based on your response

Signs of right dose

✓Therapeutic goals being met with minimal side effects

✓Stable and consistent response to treatment

✓Lab values or clinical markers trending in the right direction

✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•PACAP-38 vial (lyophilized powder or solution)

•Bacteriostatic water or sterile sodium chloride for reconstitution

•Alcohol swabs for cleaning vial tops and injection sites

•Appropriately sized syringes with fine-gauge needles (27-30 gauge)

•Sharps disposal container

Example

Add the recommended volume of bacteriostatic water to the PACAP-38 vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Your dose of PACAP-38 is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

•Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection

•Front of thighs—middle to upper portion of the outer leg

•Back of upper arm—outer area (may need assistance from another person)

Technique

1.Wash your hands thoroughly with soap and water before handling supplies

2.Clean the injection site with an alcohol swab and let it air dry completely

3.Pinch a fold of skin at the chosen injection site

4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)

5.Inject the medication slowly and steadily over 5-10 seconds

6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab

7.Rotate injection sites to prevent tissue irritation or lipodystrophy

8.Dispose of the needle safely in a sharps container—never recap or reuse needles

Storage

Before reconstitution

Store PACAP-38 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, PACAP-38 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)

Product has been exposed to temperatures outside the recommended storage range

Product has been frozen (unless specifically designed for freeze-thaw stability)

Expiration date has passed or reconstituted solution has exceeded its use-by date

Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: Intravenous infusion—rotate sites if applicable

Maintain a consistent schedule for optimal results with PACAP-38. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is itsafe?

Safety Profile

PACAP-38 shows good tolerability in Phase II trials for migraine and pain conditions with minimal serious adverse events at IV doses of 2-6 mcg/kg. Primary side effects are transient flushing and headache (10-15% of subjects), likely related to vasodilation. Cardiovascular effects include mild heart rate increase and blood pressure changes, monitored in clinical settings. No carcinogenicity or teratogenicity in animal models; limited long-term safety data in humans.

Preclinical neurophysiology using patch-clamp electrophysiology demonstrates PACAP's PAC1 receptor mechanism with dose-dependent CREB phosphorylation (Western blot) and PKA/PKC activation pathways. Clinical trials show increased pancreatic polypeptide secretion (measured via radioimmunoassay) and neuropeptide release markers. Migraine mechanism confirmed through calcitonin gene-related peptide (CGRP) interaction studies showing complementary rather than overlapping pathways.

Common Side Effects

Experienced by some users

Flushing

Facial and truncal flushing due to vasodilation via VPAC receptor activation on vascular smooth muscle, common during IV infusion

Management: Transient and self-resolving; no treatment typically required

Tachycardia

Mild to moderate increase in heart rate during IV infusion as compensatory response to vasodilation

Management: Cardiovascular monitoring during infusion; reversible after completion

Gastrointestinal Effects

Occasional nausea and abdominal discomfort during or shortly after systemic administration

Management: Antiemetics as needed; effects typically transient

Transient Warmth Sensation

Sensation of warmth throughout the body during IV infusion due to systemic vasodilation

Management: Self-limiting during infusion; no treatment required

Less Common

•Headache and Migraine Triggering

•Hypotension

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×Severe or worsening side effects that don't improve with dose adjustment or supportive care

×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing

×Your healthcare provider recommends discontinuation based on your clinical response

×Development of any new medical condition that may be contraindicated with PACAP-38

×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)

×Abnormal lab results or clinical markers that suggest adverse effects

PACAP-38 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

✓Related peptide sharing VPAC receptor targets; combination studies elucidate receptor-specific contributions to neuroprotection

✓PACAP-38 upregulates BDNF expression; co-administration may enhance neurotrophic support in neurodegeneration models

✓PACAP-38 anti-apoptotic effects complement antioxidant strategies for synergistic neuroprotection

With medications

!Triptans - PACAP-38 triggers migraine through cranial vasodilation; triptans target the same trigeminal pathway creating pharmacological conflict

!Strong Vasodilators - Additive vasodilation through multiple pathways may cause dangerous hypotension

!PAC1 Receptor Antagonists - Direct pharmacological antagonism blocks PACAP-38 primary neuroprotective mechanism

With supplements

✓Multivitamins - Generally safe to take alongside PACAP-38. Space doses apart if taking oral formulations to ensure optimal absorption.

✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete PACAP-38 research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.